Talquetamab is a humanized bispecific antibody that binds to GPRC5D (G protein-coupled receptor class C group 5 member D) and CD3, thereby recruiting and activating T cells to mediate the killing of GPRC5D-expressing multiple myeloma (MM) cells; it exhibits antitumor activity.